Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trial

AIMS: Hyperkalaemia in heart failure patients limits use of cardioprotective renin–angiotensin–aldosterone system inhibitors (RAASi). Sodium zirconium cyclosilicate (ZS‐9) is a selective potassium ion trap, whose mechanism of action may allow for potassium binding in the upper gastrointestinal tract...

Descripción completa

Detalles Bibliográficos
Autores principales: Anker, Stefan D., Kosiborod, Mikhail, Zannad, Faiez, Piña, Ileana L., McCullough, Peter A., Filippatos, Gerasimos, van der Meer, Peter, Ponikowski, Piotr, Rasmussen, Henrik S., Lavin, Philip T., Singh, Bhupinder, Yang, Alex, Deedwania, Prakash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033065/
https://www.ncbi.nlm.nih.gov/pubmed/26011677
http://dx.doi.org/10.1002/ejhf.300

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033065/
https://www.ncbi.nlm.nih.gov/pubmed/26011677
http://dx.doi.org/10.1002/ejhf.300

Ejemplares similares